These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 11714622)
41. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct. Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679 [TBL] [Abstract][Full Text] [Related]
42. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425 [No Abstract] [Full Text] [Related]
43. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice. Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847 [TBL] [Abstract][Full Text] [Related]
44. Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct. Cardinaud S; Bouziat R; Rohrlich PS; Tourdot S; Weiss L; Langlade-Demoyen P; Burgevin A; Fiorentino S; van Endert P; Lemonnier FA AIDS; 2009 Sep; 23(15):1945-54. PubMed ID: 19644347 [TBL] [Abstract][Full Text] [Related]
45. A long-term follow-up of an HIV type 1-infected patient reveals a coincidence of Nef-directed cytotoxic T lymphocyte effectors and high incidence of epitope-deleted variants. Singh MK; Janvier G; Calvez V; Coulaud P; Rivière Y AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1265-71. PubMed ID: 11559426 [TBL] [Abstract][Full Text] [Related]
46. HIV vaccine development by computer assisted design: the GAIA vaccine. De Groot AS; Marcon L; Bishop EA; Rivera D; Kutzler M; Weiner DB; Martin W Vaccine; 2005 Mar; 23(17-18):2136-48. PubMed ID: 15755584 [TBL] [Abstract][Full Text] [Related]
47. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice. Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226 [TBL] [Abstract][Full Text] [Related]
48. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585 [TBL] [Abstract][Full Text] [Related]
49. Epitope-vaccine strategy against HIV-1: today and tomorrow. Liu Z; Xiao Y; Chen YH Immunobiology; 2003; 208(4):423-8. PubMed ID: 14748515 [TBL] [Abstract][Full Text] [Related]
50. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920 [TBL] [Abstract][Full Text] [Related]
51. The role of recombination for the coevolutionary dynamics of HIV and the immune response. Mostowy R; Kouyos RD; Fouchet D; Bonhoeffer S PLoS One; 2011 Feb; 6(2):e16052. PubMed ID: 21364750 [TBL] [Abstract][Full Text] [Related]
52. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. Ferrari G; Kostyu DD; Cox J; Dawson DV; Flores J; Weinhold KJ; Osmanov S AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1433-43. PubMed ID: 11018863 [TBL] [Abstract][Full Text] [Related]
53. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162 [TBL] [Abstract][Full Text] [Related]
55. Evolution of pathogenic viruses with special reference to the rates of synonymous and nonsynonymous substitutions. Gojobori T; Yamaguchi Y; Ikeo K; Mizokami M Jpn J Genet; 1994 Oct; 69(5):481-8. PubMed ID: 7999369 [TBL] [Abstract][Full Text] [Related]
56. Evolutionary dynamics of HIV-1 and the control of AIDS. Mullins JI; Jensen MA Curr Top Microbiol Immunol; 2006; 299():171-92. PubMed ID: 16568899 [TBL] [Abstract][Full Text] [Related]
57. The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease. Nowak MA; May RM; Anderson RM AIDS; 1990 Nov; 4(11):1095-103. PubMed ID: 2282182 [TBL] [Abstract][Full Text] [Related]